Recent News

• 02.02.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 01.29.2026 - Definium Therapeutics Appoints Roger Adsett to Board of Directors
• 01.26.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 01.20.2026 - Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care
• 01.13.2026 - Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026
• 01.12.2026 - MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
• 12.18.2025 - MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
• 12.15.2025 - MindMed Announces New Employee Inducement Grant
• 12.01.2025 - MindMed Announces New Employee Inducement Grants

Recent Filings

• 01.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.29.2026 - 3 Initial statement of beneficial ownership of securities
• 01.29.2026 - 8-K Current report
• 01.12.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 12.29.2025 - 144 Report of proposed sale of securities
• 12.29.2025 - 144 Report of proposed sale of securities
• 12.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.29.2025 - 4 Statement of changes in beneficial ownership of securities